Study #2024-1458
A phase 1a/b, open-label, multicenter study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BG-C137, an antibody-drug conjugate targeting FGFR2b, in patients with advanced solid tumors
MD Anderson Study Status
Enrolling
Treatment Agent
BG-C137
Description
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-C137 in participants with advanced solid tumors.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Advanced Solid Tumor
Study phase:
Phase I
Physician name:
Jordi Rodon Ahnert
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-844-929-4217
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.